世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
テルミサルタン市場。世界の産業動向、シェア、サイズ、成長、機会、予測 2021-2026年Telmisartan Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 The global telmisartan market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 3.5% during 2021-2026. Telmisartan is a non-peptide... もっと見る
サマリーThe global telmisartan market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 3.5% during 2021-2026.Telmisartan is a non-peptide angiotensin receptor blocker (ARB), which is used as a prescription drug for the treatment of hypertension and cardiovascular disorders. It is commonly available in tablets and oral oil suspension variants and is administered with other medications to enhance its efficacy. It exhibits antihypertensive properties and inhibits aldosterone production in the body, thereby leading to a decrease in sodium and water absorption and subsequent reduction in the blood pressure. Telmisartan also relaxes the blood vessels and promotes kidney function. However, it may cause various side effects, such as dizziness, lightheadedness, cough and sinus pain. Telmisartan Market Trends: Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing prevalence of high blood pressure, diabetes and various kidney-related disorders is providing a thrust to the market growth. Telmisartan has been proven effective in modifying genes for insulin sensitization and regulating glucose and lipid metabolism, which aids in managing chronic diabetic kidney disease and other disorders caused by sedentary lifestyles. Pharmaceutical manufacturers are also launching generic versions of telmisartan medications to provide cost-effective treatment to hypertension and cardiovascular ailments. Additionally, drug manufacturers are investing significantly in the research and development (R&D) of advanced telmisartan medications for the treatment of diabetic nephropathy, which is also contributing to the growth of the market. Other factors, including the rising geriatric population, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market further. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global telmisartan market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, indication and distribution channel. Breakup by Indication: Hypertension Cardiovascular Risk Reduction Breakup by Distribution Channel: Hospital Pharmacies Drug Stores and Retail Pharmacies Online Stores Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH , Cipla Limited, Hikma Pharmaceuticals plc, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.) and Torrent Pharmaceuticals Ltd. Key Questions Answered in This Report: How has the global telmisartan market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global telmisartan market? What are the key regional markets? What is the breakup of the market based on the indication? What is the breakup of the market based on the distribution channel? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global telmisartan market and who are the key players? What is the degree of competition in the industry? 目次1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Telmisartan Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Indication 6.1 Hypertension 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Cardiovascular Risk Reduction 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Distribution Channel 7.1 Hospital Pharmacies 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Drug Stores and Retail Pharmacies 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Online Stores 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Region 8.1 North America 8.1.1 United States 8.1.1.1 Market Trends 8.1.1.2 Market Forecast 8.1.2 Canada 8.1.2.1 Market Trends 8.1.2.2 Market Forecast 8.2 Asia-Pacific 8.2.1 China 8.2.1.1 Market Trends 8.2.1.2 Market Forecast 8.2.2 Japan 8.2.2.1 Market Trends 8.2.2.2 Market Forecast 8.2.3 India 8.2.3.1 Market Trends 8.2.3.2 Market Forecast 8.2.4 South Korea 8.2.4.1 Market Trends 8.2.4.2 Market Forecast 8.2.5 Australia 8.2.5.1 Market Trends 8.2.5.2 Market Forecast 8.2.6 Indonesia 8.2.6.1 Market Trends 8.2.6.2 Market Forecast 8.2.7 Others 8.2.7.1 Market Trends 8.2.7.2 Market Forecast 8.3 Europe 8.3.1 Germany 8.3.1.1 Market Trends 8.3.1.2 Market Forecast 8.3.2 France 8.3.2.1 Market Trends 8.3.2.2 Market Forecast 8.3.3 United Kingdom 8.3.3.1 Market Trends 8.3.3.2 Market Forecast 8.3.4 Italy 8.3.4.1 Market Trends 8.3.4.2 Market Forecast 8.3.5 Spain 8.3.5.1 Market Trends 8.3.5.2 Market Forecast 8.3.6 Russia 8.3.6.1 Market Trends 8.3.6.2 Market Forecast 8.3.7 Others 8.3.7.1 Market Trends 8.3.7.2 Market Forecast 8.4 Latin America 8.4.1 Brazil 8.4.1.1 Market Trends 8.4.1.2 Market Forecast 8.4.2 Mexico 8.4.2.1 Market Trends 8.4.2.2 Market Forecast 8.4.3 Others 8.4.3.1 Market Trends 8.4.3.2 Market Forecast 8.5 Middle East and Africa 8.5.1 Market Trends 8.5.2 Market Breakup by Country 8.5.3 Market Forecast 9 SWOT Analysis 9.1 Overview 9.2 Strengths 9.3 Weaknesses 9.4 Opportunities 9.5 Threats 10 Value Chain Analysis 11 Porters Five Forces Analysis 11.1 Overview 11.2 Bargaining Power of Buyers 11.3 Bargaining Power of Suppliers 11.4 Degree of Competition 11.5 Threat of New Entrants 11.6 Threat of Substitutes 12 Price Analysis 13 Competitive Landscape 13.1 Market Structure 13.2 Key Players 13.3 Profiles of Key Players 13.3.1 Abbott Laboratories 13.3.1.1 Company Overview 13.3.1.2 Product Portfolio 13.3.1.3 Financials 13.3.1.4 SWOT Analysis 13.3.2 Aurobindo Pharma USA 13.3.2.1 Company Overview 13.3.2.2 Product Portfolio 13.3.2.3 Financials 13.3.3 Boehringer Ingelheim International GmbH 13.3.3.1 Company Overview 13.3.3.2 Product Portfolio 13.3.4 Cipla Limited 13.3.4.1 Company Overview 13.3.4.2 Product Portfolio 13.3.4.3 Financials 13.3.4.4 SWOT Analysis 13.3.5 Hikma Pharmaceuticals plc 13.3.5.1 Company Overview 13.3.5.2 Product Portfolio 13.3.5.3 Financials 13.3.5.4 SWOT Analysis 13.3.6 Jubilant Cadista Pharmaceutical 13.3.6.1 Company Overview 13.3.6.2 Product Portfolio 13.3.7 Sanofi S.A. 13.3.7.1 Company Overview 13.3.7.2 Product Portfolio 13.3.7.3 Financials 13.3.7.4 SWOT Analysis 13.3.8 Solco Healthcare (Prinston Pharmaceutical Inc.) 13.3.8.1 Company Overview 13.3.8.2 Product Portfolio 13.3.9 Torrent Pharmaceuticals Ltd 13.3.9.1 Company Overview 13.3.9.2 Product Portfolio 13.3.9.3 Financials 13.3.9.4 SWOT Analysis
SummaryThe global telmisartan market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 3.5% during 2021-2026.Telmisartan is a non-peptide angiotensin receptor blocker (ARB), which is used as a prescription drug for the treatment of hypertension and cardiovascular disorders. It is commonly available in tablets and oral oil suspension variants and is administered with other medications to enhance its efficacy. It exhibits antihypertensive properties and inhibits aldosterone production in the body, thereby leading to a decrease in sodium and water absorption and subsequent reduction in the blood pressure. Telmisartan also relaxes the blood vessels and promotes kidney function. However, it may cause various side effects, such as dizziness, lightheadedness, cough and sinus pain. Telmisartan Market Trends: Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing prevalence of high blood pressure, diabetes and various kidney-related disorders is providing a thrust to the market growth. Telmisartan has been proven effective in modifying genes for insulin sensitization and regulating glucose and lipid metabolism, which aids in managing chronic diabetic kidney disease and other disorders caused by sedentary lifestyles. Pharmaceutical manufacturers are also launching generic versions of telmisartan medications to provide cost-effective treatment to hypertension and cardiovascular ailments. Additionally, drug manufacturers are investing significantly in the research and development (R&D) of advanced telmisartan medications for the treatment of diabetic nephropathy, which is also contributing to the growth of the market. Other factors, including the rising geriatric population, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market further. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global telmisartan market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, indication and distribution channel. Breakup by Indication: Hypertension Cardiovascular Risk Reduction Breakup by Distribution Channel: Hospital Pharmacies Drug Stores and Retail Pharmacies Online Stores Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH , Cipla Limited, Hikma Pharmaceuticals plc, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.) and Torrent Pharmaceuticals Ltd. Key Questions Answered in This Report: How has the global telmisartan market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global telmisartan market? What are the key regional markets? What is the breakup of the market based on the indication? What is the breakup of the market based on the distribution channel? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global telmisartan market and who are the key players? What is the degree of competition in the industry? Table of Contents1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Telmisartan Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Indication 6.1 Hypertension 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Cardiovascular Risk Reduction 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Distribution Channel 7.1 Hospital Pharmacies 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Drug Stores and Retail Pharmacies 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Online Stores 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Region 8.1 North America 8.1.1 United States 8.1.1.1 Market Trends 8.1.1.2 Market Forecast 8.1.2 Canada 8.1.2.1 Market Trends 8.1.2.2 Market Forecast 8.2 Asia-Pacific 8.2.1 China 8.2.1.1 Market Trends 8.2.1.2 Market Forecast 8.2.2 Japan 8.2.2.1 Market Trends 8.2.2.2 Market Forecast 8.2.3 India 8.2.3.1 Market Trends 8.2.3.2 Market Forecast 8.2.4 South Korea 8.2.4.1 Market Trends 8.2.4.2 Market Forecast 8.2.5 Australia 8.2.5.1 Market Trends 8.2.5.2 Market Forecast 8.2.6 Indonesia 8.2.6.1 Market Trends 8.2.6.2 Market Forecast 8.2.7 Others 8.2.7.1 Market Trends 8.2.7.2 Market Forecast 8.3 Europe 8.3.1 Germany 8.3.1.1 Market Trends 8.3.1.2 Market Forecast 8.3.2 France 8.3.2.1 Market Trends 8.3.2.2 Market Forecast 8.3.3 United Kingdom 8.3.3.1 Market Trends 8.3.3.2 Market Forecast 8.3.4 Italy 8.3.4.1 Market Trends 8.3.4.2 Market Forecast 8.3.5 Spain 8.3.5.1 Market Trends 8.3.5.2 Market Forecast 8.3.6 Russia 8.3.6.1 Market Trends 8.3.6.2 Market Forecast 8.3.7 Others 8.3.7.1 Market Trends 8.3.7.2 Market Forecast 8.4 Latin America 8.4.1 Brazil 8.4.1.1 Market Trends 8.4.1.2 Market Forecast 8.4.2 Mexico 8.4.2.1 Market Trends 8.4.2.2 Market Forecast 8.4.3 Others 8.4.3.1 Market Trends 8.4.3.2 Market Forecast 8.5 Middle East and Africa 8.5.1 Market Trends 8.5.2 Market Breakup by Country 8.5.3 Market Forecast 9 SWOT Analysis 9.1 Overview 9.2 Strengths 9.3 Weaknesses 9.4 Opportunities 9.5 Threats 10 Value Chain Analysis 11 Porters Five Forces Analysis 11.1 Overview 11.2 Bargaining Power of Buyers 11.3 Bargaining Power of Suppliers 11.4 Degree of Competition 11.5 Threat of New Entrants 11.6 Threat of Substitutes 12 Price Analysis 13 Competitive Landscape 13.1 Market Structure 13.2 Key Players 13.3 Profiles of Key Players 13.3.1 Abbott Laboratories 13.3.1.1 Company Overview 13.3.1.2 Product Portfolio 13.3.1.3 Financials 13.3.1.4 SWOT Analysis 13.3.2 Aurobindo Pharma USA 13.3.2.1 Company Overview 13.3.2.2 Product Portfolio 13.3.2.3 Financials 13.3.3 Boehringer Ingelheim International GmbH 13.3.3.1 Company Overview 13.3.3.2 Product Portfolio 13.3.4 Cipla Limited 13.3.4.1 Company Overview 13.3.4.2 Product Portfolio 13.3.4.3 Financials 13.3.4.4 SWOT Analysis 13.3.5 Hikma Pharmaceuticals plc 13.3.5.1 Company Overview 13.3.5.2 Product Portfolio 13.3.5.3 Financials 13.3.5.4 SWOT Analysis 13.3.6 Jubilant Cadista Pharmaceutical 13.3.6.1 Company Overview 13.3.6.2 Product Portfolio 13.3.7 Sanofi S.A. 13.3.7.1 Company Overview 13.3.7.2 Product Portfolio 13.3.7.3 Financials 13.3.7.4 SWOT Analysis 13.3.8 Solco Healthcare (Prinston Pharmaceutical Inc.) 13.3.8.1 Company Overview 13.3.8.2 Product Portfolio 13.3.9 Torrent Pharmaceuticals Ltd 13.3.9.1 Company Overview 13.3.9.2 Product Portfolio 13.3.9.3 Financials 13.3.9.4 SWOT Analysis
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（その他）の最新刊レポート
IMARC Services Private Limited. 社の最新刊レポート
本レポートと同じKEY WORD（industry）の最新刊レポート
よくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/04 10:27 147.72 円 163.39 円 196.69 円 |
